
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA is a clinical-stage biopharmaceutical company specializing in neurodegenerative diseases, leveraging its proprietary technology platforms to develop innovative therapeutic and diagnostic products targeting misfolded proteins. The NLRP3 program and the promising results from the PD active immunotherapy ACI-7104.056, which has shown a 20x increase in antibodies against pathogenic variants of aSyn, significantly enhance the company’s potential for advancement and success in the market. Additionally, the adoption of safer delivery methods for monoclonal antibodies, as evidenced by historical successful treatments, aligns AC Immune's pipeline with current trends favoring efficacious and patient-friendly treatment solutions in the Alzheimer's disease landscape.
Bears say
AC Immune SA reported a net operating loss of CHF16.2 million for the quarter, indicating significant financial challenges. The company is exposed to numerous industry-specific risks, including the potential for unexpected clinical outcomes, regulatory uncertainties, and the complexities of navigating an increasingly competitive and price-sensitive market for its therapeutic and diagnostic products. These factors contribute to a negative outlook as the company continues to grapple with maintaining financial viability while pursuing its ambitious goals in the neurodegenerative disease sector.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares